Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 606-611

  Anaissie, Elias J ^a   Mattiuzzi, Gloria N ^b   Miller, Carole B ^c   Noskin, Gary A ^d   Gurwith, Marc J ^e   Mamelok, Richard D ^e   Pietrelli, Larry A ^e  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Unidad Onco Hematologica   (Argentina)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; CREATININE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; CANDIDA; CHILD; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LEG PAIN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031916650     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.606     Document Type: Article

References (26)

1. Allende, M. C., J. W. Lee, P. Francis, K. Garrett, H. Dollenberg, J. Berenguer, C. A. Lyman, P. A. Pizzo, and T. J. Walsh. 1994. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob. Agents Chemother. 38:518-522.
2. Anaissie, E. J., and M. J. Gurwith. 1995. Safety and efficacy of amphotericin B colloidal dispersion (ABCD). In 19th International Chemotherapy Conference, Montreal, Canada, July 16-21.
3. Anaissie, E. J., and H. Pinczowski. 1993. Invasive candidiasis during granulocytopenia. Recent Results Cancer Res. 132:137-145.
4. Anaissie, E. J., M. White, O. Uzun, C. Singer, G. P. Bodey, D. Matzke, N. Azarnia, and G. Lopez-Berestein. 1995. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial, abstr. LM21, p. 330. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Bowden, R. A., M. Cays, T. Gooley, R. D. Mamelok, and J. vanBurik. 1996. Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. 173:1208-1215.
6. Butler, W. T., J. E. Bennett, D. W. Ailing, P. T. Wertlake, J. P. Utz, and G. J. Hill II. 1964. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann. Intern. Med. 61:175-187.
7. Clements, J. S., Jr., and J. E. Peacock, Jr. 1990. Amphotericin B revisited: reassessment of toxicity. Am. J. Med. 88:22N-27N.
8. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:1-7.
9. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.
10. EORTC International Antimicrobial Therapy Cooperative Group. 1989. Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med. 86:668-672.
11. Guo, L. S., R. M. Fielding, D. D. Lasic, R. L. Hamilton, and D. Mufson. 1991. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75:45-54.
12. Guo, L. S., R. M. Fielding, and D. Mufson. 1991. Pharmacokinetic study of a novel amphotericin B colloidal dispersion with improved therapeutic index. Ann. N. Y. Acad. Sci. 618:586-588.
13. Hanson, L. H., and D. A. Stevens. 1992. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:486-488.
14. Hiemenz, J. W., J. Lister, E. J. Anaissie, M. H. White, M. Dinubile, J. Silber, G. Horwith, and L. W. Lee. 1995. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood 86:3383. (Abstract.)
15. Hoitsma, A. J., J. F. Wetzels, and R. A. Koene. 1991. Drug-induced nephrotoxicity: aetiology, clinical features and management. Drug Saf. 6:131-147.
16. Holleran, W. M., J. R. Wilbur, and M. W. DeGregorio. 1985. Empiric amphotericin B therapy in patients with acute leukemia. Rev. Infect. Dis. 7:619-624.
17. Hosteller, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36:2656-2660.
18. Janknegt, R., S. de Marie, I. A. Bakker-Woudenberg, and D. J. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-291.
19. Medoff, G., W. E. Dismukes, D. Pappagianis, R. Diamond, H. A. Gallis, and D. Drutz. 1992. Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Clin. Infect. Dis. 15(Suppl. 1):S274-S281.
20. Meunier, F., H. G. Prentice, and O. Ringden. 1991. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28(Suppl. B):83-91.
21. Oppenheim, B. A., R. Herbrecht, and S. Kusne. 1995. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. 21:1145-1153.
22. Ringden, O., F. Meunier, J. Tollemar, P. Ricci, S. Tura, E. Kuse, M. A. Viviani, N. C. Gorin, J. Klastersky, P. Fenaux, H. G. Prentice, and G. Ksionski. 1991. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl. B):73-82.
23. Sanders, S. W., K. N. Buchi, M. S. Goddard, J. K. Lang, and K. G. Tolman. 1991. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 35:1029-1034.
24. Sharkey, P. K., J. R. Graybill, E. S. Johnson, S. G. Hausrath, R. B. Pollard, A. Kolokathis, D. Mildvan, P. Fan-Havard, R. H. Eng, T. F. Patterson, J. C. Pottage, Jr., M. S. Simberkoff, J. Wolf, R. D. Meyer, R. Gupta, L. W. Lee, and D. S. Gordon. 1996. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22:315-321.
25. Stamm, A. M., R. B. Diasio, W. E. Dismukes, S. Shadomy, G. A. Cloud, C. A. Bowles, G. H. Karam, and A. Espinel-Ingroff. 1987. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am. J. Med. 83:236-242.
26. White, M. H., R. A. Bowden, E. Sandler, M. L. Graham, G. Noskin, J. R. Wingard, M. Goldman, A. McCabe, J. S. Lin, M. Gurwith, and C. B. Miller. 1996. Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B (AmB) in the empiric treatment of febrile neutropenic patients. Blood 88: 1196.